China Issues Deepening Health Care Reform Plan To Reign In Drug Prices
This article was originally published in PharmAsia News
Prices for pharmaceuticals widely used in clinics could be the target of efforts by the Chinese government to curb costs. At the same time, an aggressive move to stamp out kickbacks for drug sales is under way as China’s federal cabinet, or State Council, moves to deepen health care reforms.
You may also be interested in...
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.